Critical Survey: Iterum Therapeutics (NASDAQ:ITRM) and AstraZeneca (NYSE:AZN)

AstraZeneca (NYSE:AZN – Get Free Report) and Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, institutional ownership, valuation and dividends.

Insider & Institutional Ownership

20.4% of AstraZeneca shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 2.0% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

AstraZeneca has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.96, meaning that its stock price is 196% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings for AstraZeneca and Iterum Therapeutics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AstraZeneca 0 3 16 0 2.84
Iterum Therapeutics 1 2 0 0 1.67

AstraZeneca presently has a consensus price target of $206.67, suggesting a potential upside of 14.68%. Given AstraZeneca’s stronger consensus rating and higher possible upside, research analysts clearly believe AstraZeneca is more favorable than Iterum Therapeutics.

Profitability

This table compares AstraZeneca and Iterum Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
AstraZeneca 17.68% 31.85% 13.62%
Iterum Therapeutics N/A N/A -65.54%

Valuation & Earnings

This table compares AstraZeneca and Iterum Therapeutics”s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
AstraZeneca $58.74 billion 4.76 $10.22 billion $7.07 25.49
Iterum Therapeutics $390,000.00 4.10 -$24.77 million ($0.75) -0.04

AstraZeneca has higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a lower price-to-earnings ratio than AstraZeneca, indicating that it is currently the more affordable of the two stocks.

Summary

AstraZeneca beats Iterum Therapeutics on 12 of the 14 factors compared between the two stocks.

About AstraZeneca

(Get Free Report)

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries. AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.

About Iterum Therapeutics

(Get Free Report)

Iterum Therapeutics plc is a pharmaceutical company focused on developing and commercializing antibiotics for bacterial infections, including infections caused by drug-resistant pathogens. The company is headquartered in Ireland and has focused its commercial efforts on the U.S. market. Its lead product is sulopenem, a penem-class antibiotic developed in oral and intravenous formulations. The oral formulation, marketed as Orlynvah, combines sulopenem etzadroxil with probenecid. In October 2024, the U.S. Food and Drug Administration approved Orlynvah for certain uncomplicated urinary tract infections in adult women who have limited or no alternative oral antibacterial treatment options.

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.